Hemolytic Uremic Syndrome in Emergency Medicine
- Author: Audrey J Tan, DO; Chief Editor: Steven C Dronen, MD, FAAEM more...
Hemolytic uremic syndrome (HUS) is primarily a disease of infancy and early childhood and is classically characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In 1955, Gasser et al first described hemolytic uremic syndrome as a self-limited illness associated with a prodrome of diarrhea that resulted in spontaneous recovery. Though the description of this childhood illness has not changed significantly through the years, additional insight into the pathology and disease process have come to light recently.
Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) fall into the broader category of thrombotic microangiopathies (TMA). Thrombotic microangiopathies are characterized by the involvement of widespread occlusive microvascular thromboses resulting in thrombocytopenia, microangiopathic hemolytic anemia, and variable signs and symptoms of end-organ ischemia. Though recent research has revealed that the two disease processes have underlying similarities, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura have historically been considered two separate disease entities.
Two predominant types of HUS are identified: one type involves diarrhea (D+) and the other, D- or atypical, does not.
D+ HUS is the classic form, accounting for 95% of cases of hemolytic uremic syndrome in children. This form of hemolytic uremic syndrome occurs predominantly in children and is preceded by a prodrome of diarrhea, most commonly caused by an infection by shiga-toxin producing Escherichia coli.
Specifically, E coli serotype O157:H7 has been associated with more than 80% of infections leading to hemolytic uremic syndrome. The shiga-like toxin affects endothelial cells and initiates intravascular thrombogenesis. After entering the circulation via the gastrointestinal mucosa, the toxin preferentially localizes to the kidneys, inhibiting protein synthesis and eventually leading to cell necrosis or apoptosis. Endothelial cell damage subsequently potentiates renal microvascular thrombosis by promoting activation of the blood coagulation cascade. Platelet aggregation results in a consumptive thrombocytopenia. Microangiopathic hemolytic anemia results from mechanical damage to red blood cells circulating through partially occluded microcirculation.
E coli O157:H7 is not normally found in human intestinal flora but is present in 1% of healthy cattle. Thus, meat may become contaminated during animal slaughter and processing. The most common form of transmission to children in the United States is ingestion of undercooked meat containing viable bacteria. Ingesting unpasteurized fruits and juices, coming into contact with unchlorinated water, and person-to-person transmission in daycare or long-term care facilities are alternate routes of transmission.
D- HUS accounts for the remaining 5% of cases of hemolytic uremic syndrome and its etiology, age at onset, and clinical presentations are far more varied. Unlike D+ HUS, D- HUS is not preceded by an identifiable gastrointestinal infection. The pathogenesis of D- HUS has been the focus of current research and has, thus far, been associated with complement dysregulation in up to 50% of cases. Specifically, mutations in complement regulatory protein factor H, factor I, or factor B or autoantibodies against factor H have all been implicated. These mutations result in inability to suppress complement activation and for reasons that are not completely understood, the glomerular endothelium is particularly susceptible to these changes.
Clinically, D- HUS has been associated with various nonenteric infections, viruses, drugs, malignancies, transplantation, pregnancy, and other underlying medical conditions such as scleroderma and antiphospholipid syndrome. Infections caused by Streptococcus pneumoniae has been linked to 40% of D- HUS cases. Categories of drugs that have been most frequently associated with D- HUS include anticancer molecules (mitomycin, cisplatin, bleomycin, and gemcitabine), immunotherapeutics (cyclosporine, tacrolimus, OKT3, IFN, and quinidine), and antiplatelet agents (ticlopidine and clopidogrel).
Malignancies found in conjunction with hemolytic uremic syndrome include prostatic, gastric, and pancreatic cancers. Familial forms of D- HUS exist but account for fewer than 3% of cases. Unlike D+ HUS, only 4.7% of D-HUS cases in the United States involve children.
In contrast to hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP) presents with the classic pentad of microangiopathic hemolytic anemia, thrombocytopenia, prominent neurologic symptoms, fever and a milder form of renal failure. The pathophysiology of thrombotic thrombocytopenic purpura is different in that, as opposed to endothelial cell injury, thrombotic thrombocytopenic purpura is thought to be caused by a deficiency in the metalloprotease ADAMTS13, which is involved in the regulation of von Willebrand factor. A lack of this protein results in spontaneous platelet aggregation and the widespread deposition of platelet-rich thrombi in the microvasculature of various organs, most notably the heart, brain, and kidneys.
Current research has demonstrated that, though a deficiency of ADAMTS13 clearly diagnoses thrombotic thrombocytopenic purpura, patients with D- HUS also share this finding. Current research suggests that these two illnesses share a similar pathophysiology and may be variants of the same disease spectrum.
The overall incidence of D+ HUS is estimated to be approximately 2.1 cases per 100,000 persons per year, with a peak incidence in children who are younger than 5 years (6.1 cases per 100,000 per year). The lowest rate is in adults aged 50-59 years (0.5 cases per 100,000 per year). 
Incidence tends to parallel the seasonal fluctuation of E coli O157:H7 infection, which peaks between June and September. 
Incidence of D- HUS in children is approximately 2 cases per year per 100,000 total population. 
See the list below:
In D+ HUS, the mortality rate is between 3% and 5%. Older children and adults often have poorer prognoses. Death is nearly always associated with severe extrarenal disease, including severe central nervous system (CNS) involvement. Approximately two thirds of children with D+ HUS require dialysis. 
In cases of D- HUS, overall mortality rate approaches 26%.
Hemolytic uremic syndrome has no predilection for a specific race.
Hemolytic uremic syndrome has no predilection for either sex.
See the list below:
D+ HUS is typically observed in infants and children, especially those aged 6 months to 4 years.
D- HUS is variable in its age of presentation.
Gasser WC, et al. Hamolytisch uramische syndrome: Bilaterale Nierenridennekrosen bei akuten erworbenen hamolytischen Anamien. Schweiz Med Wochenschr. 1955. 85:905.
Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005 Apr. 16(4):1035-50. [Medline].
Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008 Oct. 23(10):1749-60. [Medline].
Soliris (eculizumab) [package insert]. Cheshire, CT: Alexion Pharmaceutical. 2011.
Loirat C, Babu S, Furman R, Sheerin N, Cohen D, Gaber O, et al. Eculizumab Efficacy and Safety in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion [poster]. Presented at the 16th Congress of European Hematology Association (EHA). 2011. London, UK.
Loirat C, Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, et al. A Phase II Study of Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome Receiving Chronic Plasma Exchange/Infusion [poster]. Presented at the 16th Congress of European Hematology Association (EHA). 2011. London, UK.
Santos AH Jr, Casey MJ, Wen X, Zendejas I, Faldu C, Rehman S, et al. Outcome of kidney transplants for adults with hemolytic uremic syndrome in the U.S.: a ten-year database analysis. Ann Transplant. 2014 Jul 21. 19:353-61. [Medline].
Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005 Jun. 115(6):e673-80. [Medline].
Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 1997 Jul. 100(1):E12. [Medline].
Corrigan JJ Jr, Boineau FG. Hemolytic-uremic syndrome. Pediatr Rev. 2001 Nov. 22(11):365-9. [Medline].
Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?. J Am Soc Nephrol. 2007 Sep. 18(9):2457-60. [Medline].
Foerster J. Hemolytic Uremic Syndrome. Wintrobe's Clinical Hematology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1993. 1215-19.
Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003 Sep 10. 290(10):1360-70. [Medline].
Gordjani N, Sutor AH, Zimmerhackl LB, Brandis M. Hemolytic uremic syndromes in childhood. Semin Thromb Hemost. 1997. 23(3):281-93. [Medline].
Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol. 1987 Jul. 24(3):194-201. [Medline].
Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA. 1981 Oct 23-30. 246(17):1931-3. [Medline].
Hayward CP, Sutton DM, Carter WH Jr, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med. 1994 May 9. 154(9):982-7. [Medline].
Hoffman. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000.
Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014 Aug. 32(3):649-71. [Medline].
Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr. 2001 Mar. 138(3):412-7. [Medline].
Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica. 2007 Jul. 92(7):878-80. [Medline].
Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med. 1990 Oct 25. 323(17):1161-7. [Medline].
Matsumae T, Takebayashi S, Naito S. The clinico-pathological characteristics and outcome in hemolytic-uremic syndrome of adults. Clin Nephrol. 1996 Mar. 45(3):153-62. [Medline].
Mbonu CC, Davison DL, El-Jazzar KM, Simon GL. Clostridium difficile colitis associated with hemolytic-uremic syndrome. Am J Kidney Dis. 2003 May. 41(5):E14. [Medline].
Miller JM Jr, Pastorek JG 2nd. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy. Clin Obstet Gynecol. 1991 Mar. 34(1):64-71. [Medline].
Niaudet P, Gagnadoux MF, Broyer M, Salomon R. Hemolytic-uremic syndrome: hereditary forms and forms associated with hereditary diseases. Adv Nephrol Necker Hosp. 2000. 30:261-80. [Medline].
Pene F, Vigneau C, Auburtin M, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med. 2005 Jan. 31(1):71-8. [Medline].
Razzaq S. Hemolytic uremic syndrome: an emerging health risk. Am Fam Physician. 2006 Sep 15. 74(6):991-6. [Medline].
Remuzzi G. Hemolytic uremic syndrome: past and present. Am J Kidney Dis. 2000 Nov. 36(5):LIV-VI. [Medline].
Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995 Jul. 48(1):2-19. [Medline].
Roberts JR. Streptococcal Pharyngitis. Emergency Medicine News. 2000.
Roberts JR. HUS and TTP Associated with Escherichia Coli 0157:H7. Emerg Med News. 2004.
Ruggenenti P, Remuzzi G. Treatment of adult hemolytic-uremic syndrome. Adv Nephrol Necker Hosp. 2000. 30:83-94. [Medline].
Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA. 2002 Aug 28. 288(8):996-1001. [Medline].
Schieppati A, Ruggenenti P, Cornejo RP, et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol. 1992 May. 2(11):1640-4. [Medline].
Sens YA, Miorin LA, Silva HG, Malheiros DM, Filho DM, Jabur P. Acute renal failure due to hemolytic uremic syndrome in adult patients. Ren Fail. 1997 Mar. 19(2):279-82. [Medline].
Siegler RL, Pavia AT, Hansen FL, Christofferson RD, Cook JB. Atypical hemolytic-uremic syndrome: a comparison with postdiarrheal disease. J Pediatr. 1996 Apr. 128(4):505-11. [Medline].
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25. 365(9464):1073-86. [Medline].
Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am. 2001 Sep. 30(3):735-51. [Medline].
Van Gool S, Brock P, Van Laer P, Van Damme-Lombaerts R, Proesmans W, Casteels-Van Daele M. Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine. Eur J Pediatr. 1994 Jul. 153(7):517-9. [Medline].
Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 1. 102(1):60-8. [Medline].
Walters MD, Matthei IU, Kay R, Dillon MJ, Barratt TM. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol. 1989 Apr. 3(2):130-4. [Medline].
Wegner DL, Witte DL, Schrantz RD. Insensitivity of rapid antigen detection methods and single blood agar plate culture for diagnosing streptococcal pharyngitis. JAMA. 1992 Feb 5. 267(5):695-7. [Medline].
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29. 342(26):1930-6. [Medline].